{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(1)"],"submitter":["Kapoor A"],"pubmed_abstract":["<h4>Introduction</h4>ALK inhibitors are one of the success stories in precision medicine for treating patients with advanced ALK-positive NSCLC. Nevertheless, developing countries have substantial constraints in using ALK inhibitors, with limited data from India.<h4>Methods</h4>An audit of a prospectively collected database of patients with advanced ALK-positive NSCLC treated from January 2013 to March 2018 was conducted. The SPSS version 20.0 was used for statistical analysis.<h4>Results</h4>A total of 441 patients were available for analysis; 62.5% were males, median age was 50 (range: 19-75) years, and 78.3% had Eastern Cooperative Oncology Group performance status of 0 to 1. When all the lines of therapies were included in the analysis, ALK inhibitors could be used in 379 (85.9%) of th"],"journal":["JTO clinical and research reports"],"pagination":["100443"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9841022"],"repository":["biostudies-literature"],"pubmed_title":["Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings."],"pmcid":["PMC9841022"],"pubmed_authors":["Shetty O","Joshi A","Janu A","Kumar R","Patil V","Singh AK","Mahajan A","Noronha V","Chougule A","Menon N","Pai T","Kapoor A","Prabhash K","Kumar A"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings.","description":"<h4>Introduction</h4>ALK inhibitors are one of the success stories in precision medicine for treating patients with advanced ALK-positive NSCLC. Nevertheless, developing countries have substantial constraints in using ALK inhibitors, with limited data from India.<h4>Methods</h4>An audit of a prospectively collected database of patients with advanced ALK-positive NSCLC treated from January 2013 to March 2018 was conducted. The SPSS version 20.0 was used for statistical analysis.<h4>Results</h4>A total of 441 patients were available for analysis; 62.5% were males, median age was 50 (range: 19-75) years, and 78.3% had Eastern Cooperative Oncology Group performance status of 0 to 1. When all the lines of therapies were included in the analysis, ALK inhibitors could be used in 379 (85.9%) of th","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-03-15T13:47:48.884Z","creation":"2025-04-04T14:28:10.249Z"},"accession":"S-EPMC9841022","cross_references":{"pubmed":["36654881"],"doi":["10.1016/j.jtocrr.2022.100443"]}}